X
All Data
Upgrade this company profile, update & customize all content// Ask PharmaCompass, click HERE
Lead Product(s): EVT894
Therapeutic Area: Infections and Infectious Diseases Product Name: SAR440894
Highest Development Status: Phase I Product Type: Large molecule
Partner/Sponsor/Collaborator: National Institutes of Health
Deal Size: Not Applicable Upfront Cash: Not Applicable
Deal Type: Not Applicable January 28, 2021
Details:
EVT894 is a fully human monoclonal antibody that targets a viral protein and has shown potent neutralising activity in in vitro and in vivo models. First Dose of Evt894, a Monoclonal Antibody Against Chikungunya Virus Administered to A Healthy Participant IN A Phase I Study.
Upgrade this company profile, update & customize all content// Ask PharmaCompass, click HERE
Lead Product(s): MVA-SARS-2-S vaccine
Therapeutic Area: Infections and Infectious Diseases Product Name: MVA-SARS-2-S vaccine
Highest Development Status: Phase I Product Type: Vaccine
Partner/Sponsor/Collaborator: Not Applicable
Deal Size: Not Applicable Upfront Cash: Not Applicable
Deal Type: Not Applicable October 02, 2020
Details:
The trial of the vaccine, which has been developed with the German Centre for Infection Research (DZIF), will be conducted on 30 participants aged between 18 and 55 who will receive two vaccinations at four-week intervals.
Upgrade this company profile, update & customize all content// Ask PharmaCompass, click HERE
Lead Product(s): mRNA based vaccine
Therapeutic Area: Infections and Infectious Diseases Product Name: CVnCoV
Highest Development Status: Phase I Product Type: Vaccine
Partner/Sponsor/Collaborator: German Federal Ministry of Education and Research
Deal Size: $297.8 million Upfront Cash: Undisclosed
Deal Type: Funding September 04, 2020
Details:
Funding will support the development of its COVID-19 vaccine candidate. In July 2020, CureVac had applied to a grant as part of a special program to accelerate the research and development of urgently needed vaccines against SARS-CoV-2.
Upgrade this company profile, update & customize all content// Ask PharmaCompass, click HERE
Lead Product(s): mRNA based vaccine
Therapeutic Area: Infections and Infectious Diseases Product Name: CVnCoV
Highest Development Status: Phase I Product Type: Vaccine
Partner/Sponsor/Collaborator: BofA Securities
Deal Size: Undisclosed Upfront Cash: Undisclosed
Deal Type: Public Offering August 10, 2020
Details:
The net proceeds will support Company’s mRNA vaccine program against SARS-CoV-2 through the completion of Phase 3; will be used to fund the expansion of the Company’s short term manufacturing capabilities; to advance the Company’s lead oncology program, CV8102.
Upgrade this company profile, update & customize all content// Ask PharmaCompass, click HERE
Lead Product(s): mRNA based vaccine
Therapeutic Area: Infections and Infectious Diseases Product Name: CVnCoV
Highest Development Status:
Active Pharmaceutical Ingredients
Finished Drug Formulations
Prices
Excipients
Services
Marketplace
